These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 19428401)

  • 21. The effect of dopamine agonists on cognitive functions in non-demented early-mild Parkinson's disease patients.
    Brusa L; Pavino V; Massimetti MC; Bove R; Iani C; Stanzione P
    Funct Neurol; 2013; 28(1):13-7. PubMed ID: 23731911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of internal clock and memory disorders on duration reproductions and duration productions in patients with Parkinson's disease.
    Perbal S; Deweer B; Pillon B; Vidailhet M; Dubois B; Pouthas V
    Brain Cogn; 2005 Jun; 58(1):35-48. PubMed ID: 15878725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are dopaminergic pathways involved in theory of mind? A study in Parkinson's disease.
    Péron J; Vicente S; Leray E; Drapier S; Drapier D; Cohen R; Biseul I; Rouaud T; Le Jeune F; Sauleau P; Vérin M
    Neuropsychologia; 2009 Jan; 47(2):406-14. PubMed ID: 18845171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levodopa improves time-based prospective memory in Parkinson's disease.
    Costa A; Peppe A; Brusa L; Caltagirone C; Gatto I; Carlesimo GA
    J Int Neuropsychol Soc; 2008 Jul; 14(4):601-10. PubMed ID: 18577289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching from pergolide to pramipexole in patients with Parkinson's disease.
    Hanna PA; Ratkos L; Ondo WG; Jankovic J
    J Neural Transm (Vienna); 2001; 108(1):63-70. PubMed ID: 11261747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Motor procedural learning in Parkinson's disease.
    Muslimovic D; Post B; Speelman JD; Schmand B
    Brain; 2007 Nov; 130(Pt 11):2887-97. PubMed ID: 17855374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
    Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
    Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emotional processing in Parkinson's disease. A study using functional transcranial doppler sonography.
    Troisi E; Peppe A; Pierantozzi M; Matteis M; Vernieri F; Stanzione P; Silvestrini M; Caltagirone C
    J Neurol; 2002 Aug; 249(8):993-1000. PubMed ID: 12195443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Age-related working memory decline in patients with Parkinson's disease].
    Tamura I; Kikuchi S; Kitagawa M; Otsuki M; Tashiro K
    No To Shinkei; 2003 Apr; 55(4):335-40. PubMed ID: 12755037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopaminergic modulation of visual-spatial working memory in Parkinson's disease.
    Costa A; Peppe A; Dell'Agnello G; Carlesimo GA; Murri L; Bonuccelli U; Caltagirone C
    Dement Geriatr Cogn Disord; 2003; 15(2):55-66. PubMed ID: 12566593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.
    Piercey MF
    Clin Neuropharmacol; 1998; 21(3):141-51. PubMed ID: 9617505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of high dose pergolide mesilate on restless legs syndrome associated with Parkinson disease].
    Imamura A; Tsuboi Y; Tanaka M; Obata T; Yamada T
    Rinsho Shinkeigaku; 2007 Apr; 47(4):156-9. PubMed ID: 17511286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
    Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A
    Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An open label trial of pergolide in Thai patients with Parkinson's disease.
    Poungvarin N; Prayoonwiwat N; Devahasatin V; Viriyavejakul A
    J Med Assoc Thai; 1996 Apr; 79(4):205-9. PubMed ID: 8708504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A functional MRI study of the effects of bromocriptine, a dopamine receptor agonist, on component processes of working memory.
    Gibbs SE; D'Esposito M
    Psychopharmacology (Berl); 2005 Aug; 180(4):644-53. PubMed ID: 16001111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
    Wakamatsu M; Iwata S; Funakoshi T; Yoshimoto M
    J Neurosci Res; 2008 Feb; 86(3):640-6. PubMed ID: 17896793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased plasma arginine vasopressin levels in dopamine agonist-treated Parkinson's disease patients.
    Arai M
    Neuro Endocrinol Lett; 2011; 32(1):39-43. PubMed ID: 21407160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease.
    Lewis SJ; Slabosz A; Robbins TW; Barker RA; Owen AM
    Neuropsychologia; 2005; 43(6):823-32. PubMed ID: 15716155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopamine receptor agonists and depression in Parkinson's disease.
    Picillo M; Rocco M; Barone P
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S81-4. PubMed ID: 20123564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of juvenile Parkinson disease and the recurrent emergence of pathologic gambling.
    Garcia RF; Ordacgi L; Mendlowicz MV; de Freitas GR; Rosso AL; Nazar BP; Fontenelle LF
    Cogn Behav Neurol; 2007 Mar; 20(1):11-4. PubMed ID: 17356338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.